Search for: "Amgen Inc. v. Apotex Inc."
Results 1 - 20
of 47
Sorted by Relevance
|
Sort by Date
11 Jul 2016, 9:59 pm
By Andrew Williams -- Last year, the Federal Circuit described the Biologics Price Competition and Innovation Act ("BPCIA") as "a riddle wrapped in a mystery inside of an enigma" in the Amgen v. [read post]
8 Nov 2015, 9:20 pm
Amgen Inc. et al. v. [read post]
25 Sep 2016, 7:00 am
For petitioners, blog articles were most often cited to construe the claims (Apotex Inc. v. [read post]
14 Nov 2017, 3:04 pm
Amgen Inc., 137 S. [read post]
8 Nov 2016, 8:23 pm
The petition of the day is: Apotex Inc. v. [read post]
15 Sep 2009, 10:54 pm
Praxair, Inc. v. [read post]
9 Aug 2016, 7:50 am
" Amgen Inc. et al v. [read post]
1 Dec 2009, 9:45 am
Apotex Corporation and Apotex Inc. [read post]
12 Dec 2014, 10:29 pm
Apotex, Inc., 550 F.3d 1075, 1082 (Fed.Cir. 2008). [read post]
24 Apr 2017, 11:12 am
Amgen and Amgen v. [read post]
12 Dec 2008, 8:42 am
See Amgen Inc. v. [read post]
7 Sep 2010, 6:10 pm
Highlights this week included: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector) Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor) Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen,… [read post]
4 Mar 2016, 12:25 pm
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
19 Mar 2014, 9:00 am
Apotex relies on hundreds of prior art documents. [read post]
18 Sep 2016, 6:03 pm
Another new petition includes the BPCIA case Apotex v. [read post]
23 Jan 2024, 3:43 am
Vanda Pharmaceuticals Inc., v. [read post]
13 Oct 2016, 6:50 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Eligibility: Trading Technologies International, Inc. v. [read post]
18 Apr 2016, 9:58 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
3 Jun 2016, 6:40 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
